Research and development in the causal treatment of lung damage financially Vienna, Austria secured 5th August 2010: APEPTICO research and development GmbH, a biotechnology company developing novel peptide-based drugs, the successful completion of a three million euro financing round announced today. Direct investment brings together existing and new investors from Germany and of Switzerland. Within the financing round APEPTICO will receive also a research funding of EUR 1.2 million from the Austrian target Agency (FFG). This three million euro financing round is distributed equally on venture capital investors (the BioScience Ventures Group Ltd and V + GmbH & co fund 2 KG) and private investors from Germany and of Switzerland. The APEPTICO products are synthetic peptides, which are alpha to convert to structural elements of the human tumor necrosis factor in efficient, safe and new medicines. Clinical of APEPTICO focuses on the treatment of acute lung damage / acute respiratory distress syndrome, severe microbial and viral infections of the lungs, lung transplants and the treatment of organ dysfunction.
The means of financing are used to carry out a phase 1 clinical study of APEPTICOs control substance AP301. AP301 enabled the reabsorption of edema fluid in the lungs and protects the endothelial – and epithelial cells of the Lung in addition a hyper permeability, caused by bacterial and viral factors. Dr. Bernhard Fischer, Managing Director of APEPTICO, said: “I am delighted that we were able to complete the second round of financing with a syndicate of venture capital and private investors. On the basis of the first financing round from May 2009, we could complete the pre-clinical development program of our control peptides AP301 and identify new peptides with improved properties. The current three million euro financing round allows us immediately to begin early clinical research and development and other peptides and additional clinical indications for work. About APEPTICO research and development company APEPTICO research and development GmbH is a private biotechnology company in Austria and developed peptide products for the treatment of life-threatening and chronic diseases.